Cargando…

Octreotide and Pasireotide Combination Treatment in Somatotroph Tumor Cells: Predominant Role of SST(2) in Mediating Ligand Effects

SIMPLE SUMMARY: First-generation somatostatin receptor ligands, such as octreotide, are the first-line medical therapy in acromegaly. Octreotide shows preferential binding for somatostatin receptor subtype 2 (SST(2)), while the second-generation ligand, pasireotide, has high affinity for multiple SS...

Descripción completa

Detalles Bibliográficos
Autores principales: Amarù, Jessica, Barbieri, Federica, Arvigo, Marica, Solari, Agnese, Bajetto, Adriana, Nista, Federica, Campana, Claudia, Gaggero, Gabriele, Prior, Alessandro, Criminelli Rossi, Diego, Zona, Gianluigi, Ferone, Diego, Florio, Tullio, Gatto, Federico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8069349/
https://www.ncbi.nlm.nih.gov/pubmed/33920241
http://dx.doi.org/10.3390/cancers13081816
_version_ 1783683216413032448
author Amarù, Jessica
Barbieri, Federica
Arvigo, Marica
Solari, Agnese
Bajetto, Adriana
Nista, Federica
Campana, Claudia
Gaggero, Gabriele
Prior, Alessandro
Criminelli Rossi, Diego
Zona, Gianluigi
Ferone, Diego
Florio, Tullio
Gatto, Federico
author_facet Amarù, Jessica
Barbieri, Federica
Arvigo, Marica
Solari, Agnese
Bajetto, Adriana
Nista, Federica
Campana, Claudia
Gaggero, Gabriele
Prior, Alessandro
Criminelli Rossi, Diego
Zona, Gianluigi
Ferone, Diego
Florio, Tullio
Gatto, Federico
author_sort Amarù, Jessica
collection PubMed
description SIMPLE SUMMARY: First-generation somatostatin receptor ligands, such as octreotide, are the first-line medical therapy in acromegaly. Octreotide shows preferential binding for somatostatin receptor subtype 2 (SST(2)), while the second-generation ligand, pasireotide, has high affinity for multiple SSTs. We aimed to elucidate whether pasireotide acts via other receptors than SST(2) in somatotroph tumors, and to investigate the potential role of the combination therapy octreotide plus pasireotide. We found that octreotide and pasireotide are superimposable in reducing GH secretion in cultured somatotroph tumor cells, as well as in inhibiting cell proliferation and intracellular pathway activity in rat GH4C1 cells (a model of somatotroph tumors). We did not find any additive/synergistic effect for the combination treatment. Furthermore, we observed that co-incubation with a SST(2)-selective antagonist reversed the inhibitory effect of both compounds. Therefore, the two drugs act mainly via SST(2) in somatotroph tumor cells, and their combination is not superior to single agent treatment. ABSTRACT: First-generation somatostatin receptor ligands (fg-SRLs), such as octreotide (OCT), represent the first-line medical therapy in acromegaly. Fg-SRLs show a preferential binding affinity for somatostatin receptor subtype-2 (SST(2)), while the second-generation ligand, pasireotide (PAS), has high affinity for multiple SSTs (SST(5) > SST(2) > SST(3) > SST(1)). Whether PAS acts via SST(2) in somatotroph tumors, or through other SSTs (e.g., SST(5)), is a matter of debate. In this light, the combined treatment OCT+PAS could result in additive/synergistic effects. We evaluated the efficacy of OCT and PAS (alone and in combination) on growth hormone (GH) secretion in primary cultures from human somatotroph tumors, as well as on cell proliferation, intracellular signaling and receptor trafficking in the rat GH4C1 cell line. The results confirmed the superimposable efficacy of OCT and PAS in reducing GH secretion (primary cultures), cell proliferation, cAMP accumulation and intracellular [Ca(2+)] increase (GH4C1 cells), without any additive effect observed for OCT+PAS. In GH4C1 cells, co-incubation with a SST(2)-selective antagonist reversed the inhibitory effect of OCT and PAS on cell proliferation and cAMP accumulation, while both compounds resulted in a robust internalization of SST(2) (but not SST(5)). In conclusion, OCT and PAS seem to act mainly through SST(2) in somatotroph tumor cells in vitro, without inducing any additive/synergistic effect when tested in combination.
format Online
Article
Text
id pubmed-8069349
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-80693492021-04-26 Octreotide and Pasireotide Combination Treatment in Somatotroph Tumor Cells: Predominant Role of SST(2) in Mediating Ligand Effects Amarù, Jessica Barbieri, Federica Arvigo, Marica Solari, Agnese Bajetto, Adriana Nista, Federica Campana, Claudia Gaggero, Gabriele Prior, Alessandro Criminelli Rossi, Diego Zona, Gianluigi Ferone, Diego Florio, Tullio Gatto, Federico Cancers (Basel) Article SIMPLE SUMMARY: First-generation somatostatin receptor ligands, such as octreotide, are the first-line medical therapy in acromegaly. Octreotide shows preferential binding for somatostatin receptor subtype 2 (SST(2)), while the second-generation ligand, pasireotide, has high affinity for multiple SSTs. We aimed to elucidate whether pasireotide acts via other receptors than SST(2) in somatotroph tumors, and to investigate the potential role of the combination therapy octreotide plus pasireotide. We found that octreotide and pasireotide are superimposable in reducing GH secretion in cultured somatotroph tumor cells, as well as in inhibiting cell proliferation and intracellular pathway activity in rat GH4C1 cells (a model of somatotroph tumors). We did not find any additive/synergistic effect for the combination treatment. Furthermore, we observed that co-incubation with a SST(2)-selective antagonist reversed the inhibitory effect of both compounds. Therefore, the two drugs act mainly via SST(2) in somatotroph tumor cells, and their combination is not superior to single agent treatment. ABSTRACT: First-generation somatostatin receptor ligands (fg-SRLs), such as octreotide (OCT), represent the first-line medical therapy in acromegaly. Fg-SRLs show a preferential binding affinity for somatostatin receptor subtype-2 (SST(2)), while the second-generation ligand, pasireotide (PAS), has high affinity for multiple SSTs (SST(5) > SST(2) > SST(3) > SST(1)). Whether PAS acts via SST(2) in somatotroph tumors, or through other SSTs (e.g., SST(5)), is a matter of debate. In this light, the combined treatment OCT+PAS could result in additive/synergistic effects. We evaluated the efficacy of OCT and PAS (alone and in combination) on growth hormone (GH) secretion in primary cultures from human somatotroph tumors, as well as on cell proliferation, intracellular signaling and receptor trafficking in the rat GH4C1 cell line. The results confirmed the superimposable efficacy of OCT and PAS in reducing GH secretion (primary cultures), cell proliferation, cAMP accumulation and intracellular [Ca(2+)] increase (GH4C1 cells), without any additive effect observed for OCT+PAS. In GH4C1 cells, co-incubation with a SST(2)-selective antagonist reversed the inhibitory effect of OCT and PAS on cell proliferation and cAMP accumulation, while both compounds resulted in a robust internalization of SST(2) (but not SST(5)). In conclusion, OCT and PAS seem to act mainly through SST(2) in somatotroph tumor cells in vitro, without inducing any additive/synergistic effect when tested in combination. MDPI 2021-04-10 /pmc/articles/PMC8069349/ /pubmed/33920241 http://dx.doi.org/10.3390/cancers13081816 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Amarù, Jessica
Barbieri, Federica
Arvigo, Marica
Solari, Agnese
Bajetto, Adriana
Nista, Federica
Campana, Claudia
Gaggero, Gabriele
Prior, Alessandro
Criminelli Rossi, Diego
Zona, Gianluigi
Ferone, Diego
Florio, Tullio
Gatto, Federico
Octreotide and Pasireotide Combination Treatment in Somatotroph Tumor Cells: Predominant Role of SST(2) in Mediating Ligand Effects
title Octreotide and Pasireotide Combination Treatment in Somatotroph Tumor Cells: Predominant Role of SST(2) in Mediating Ligand Effects
title_full Octreotide and Pasireotide Combination Treatment in Somatotroph Tumor Cells: Predominant Role of SST(2) in Mediating Ligand Effects
title_fullStr Octreotide and Pasireotide Combination Treatment in Somatotroph Tumor Cells: Predominant Role of SST(2) in Mediating Ligand Effects
title_full_unstemmed Octreotide and Pasireotide Combination Treatment in Somatotroph Tumor Cells: Predominant Role of SST(2) in Mediating Ligand Effects
title_short Octreotide and Pasireotide Combination Treatment in Somatotroph Tumor Cells: Predominant Role of SST(2) in Mediating Ligand Effects
title_sort octreotide and pasireotide combination treatment in somatotroph tumor cells: predominant role of sst(2) in mediating ligand effects
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8069349/
https://www.ncbi.nlm.nih.gov/pubmed/33920241
http://dx.doi.org/10.3390/cancers13081816
work_keys_str_mv AT amarujessica octreotideandpasireotidecombinationtreatmentinsomatotrophtumorcellspredominantroleofsst2inmediatingligandeffects
AT barbierifederica octreotideandpasireotidecombinationtreatmentinsomatotrophtumorcellspredominantroleofsst2inmediatingligandeffects
AT arvigomarica octreotideandpasireotidecombinationtreatmentinsomatotrophtumorcellspredominantroleofsst2inmediatingligandeffects
AT solariagnese octreotideandpasireotidecombinationtreatmentinsomatotrophtumorcellspredominantroleofsst2inmediatingligandeffects
AT bajettoadriana octreotideandpasireotidecombinationtreatmentinsomatotrophtumorcellspredominantroleofsst2inmediatingligandeffects
AT nistafederica octreotideandpasireotidecombinationtreatmentinsomatotrophtumorcellspredominantroleofsst2inmediatingligandeffects
AT campanaclaudia octreotideandpasireotidecombinationtreatmentinsomatotrophtumorcellspredominantroleofsst2inmediatingligandeffects
AT gaggerogabriele octreotideandpasireotidecombinationtreatmentinsomatotrophtumorcellspredominantroleofsst2inmediatingligandeffects
AT prioralessandro octreotideandpasireotidecombinationtreatmentinsomatotrophtumorcellspredominantroleofsst2inmediatingligandeffects
AT criminellirossidiego octreotideandpasireotidecombinationtreatmentinsomatotrophtumorcellspredominantroleofsst2inmediatingligandeffects
AT zonagianluigi octreotideandpasireotidecombinationtreatmentinsomatotrophtumorcellspredominantroleofsst2inmediatingligandeffects
AT feronediego octreotideandpasireotidecombinationtreatmentinsomatotrophtumorcellspredominantroleofsst2inmediatingligandeffects
AT floriotullio octreotideandpasireotidecombinationtreatmentinsomatotrophtumorcellspredominantroleofsst2inmediatingligandeffects
AT gattofederico octreotideandpasireotidecombinationtreatmentinsomatotrophtumorcellspredominantroleofsst2inmediatingligandeffects